OBJECTIVE: To determine whether the severity of valvulopathy was associated with the dosage of fen¯uramine taken by fen¯uramine-phentermine users with valvulopathy. DESIGN: Out of 105 suspected valvulopathy case reports received by the US Food and Drug Administration (FDA) among fen¯uramine-phentermine users, 74 patients meeting FDA case de®nition for valvulopathy were included in this study. Patients with severe valvulopathy were classi®ed as those either undergoing valve replacement surgery or having severe aortic or mitral regurgitation; all other patients were considered to have less severe valvulopathy. RESULTS: The proportion with severe valvulopathy increased from 20 ± 66% with increasing fen¯uramine dosage from 40 mgad to !60 mgad. Compared with patients taking`40 mgad fen¯uramine, patients taking ! 60 mgad had an adjusted odds ratio of 9.2 (95% con®dence interval 2.1 ± 40.8) for severe valvulopathy. CONCLUSION: Compared to patients with less severe valvulopathy, those with severe valvulopathy were substantially more likely to have taken ! 60 mgad fen¯uramine.
Introduction
Fen¯uramine is a serotonin-based appetite-suppressant drug which is widely used in combination with phentermine, commonly called fen-phen. On 8 July 1997, the Mayo Clinic reported 24 cases of valvular heart disease in women treated with fen-phen, 1 who had no history of valvulopathy. Subsequently, the US Food and Drug Administration (FDA) issued a Public Health Advisory requesting that physicians report additional cases of valvulopathy through MED-WATCH, a medical product reporting system established by FDA. 2 Based on results from the prevalence surveys, which consistently found a higher than expected prevalence of valvulopathy among persons exposed to fen¯uramine or dexfen¯uramine, 3 FDA announced the voluntary withdrawal of fen¯uramine and dexfen¯uramine from the market on 15 September 1998.
Although the most recent studies provide further support to the association of appetite-suppressant medications with valvulopathy, 4 ± 6 none of them provides information about the dose-effect. The purpose of this study was to determine whether the severity of valvular heart disease among fen-phen users was associated with the dosage of fen¯uramine.
Subjects and methods
Because the striking feature of the case reports received by FDA was the consistent involvement of left-sided cardiac valve lesions, FDA established its case de®nition as the existence of either mild or greater aortic regurgitation (AR), or moderate or greater mitral regurgitation (MR), or both as determined by echocardiography. At the time when fen¯uramine and dexfen¯uramine were voluntarily withdrawn from the market, FDA had received 105 fen-phen case reports. Among them, 88 (84%) met FDA de®nition of valvulopathy. After excluding 14 patients without complete information on drug exposure and covariates, the ®nal study sample consisted of 74 fen-phen patients with valvulopathy. Patients with severe valvulopathy were classi®ed as those either undergoing valve replacement surgery or having severe AR or severe MR; all other patients were considered to have less-severe valvulopathy. w 2 test was used to examine the difference in the proportion of severe valvulopathy. Logistic regression analysis was used to determine whether the severity of valvulopathy was related to the drug use, after adjusting for age, body weight at report, and the duration of drug use. No interaction terms between duration and drug use were included in the model, because of their statistical insigni®cance (P b 0.01). All statistical analyses were done using SAS version 6.12. 7
Results
Thirty-®ve out of 74 fen-phen patients (47%) were classi®ed as having severe valvulopathy, whereas 39 (53%) were classi®ed as having less severe valvulopathy. Among patients with severe valvulopathy, 17 underwent value replacement surgery, ®ve had severe AR, and 13 had severe MR. In all patients, the median dosage for fen¯uramine and phentermine was 60 mgad (range 10 ± 220 mgad) and 30 mgad (range 15 ± 60 mgad) respectively, whereas the median duration of fen-phen use was 11 months (range 1 ± 39 months). Table 1 shows that patients with severe valvulopathy tended to use higher fenuramine doses than those with less-severe valvulopathy (82% of severe vs 38% of less-severe patients took !60 mgad, w 2 15.08, P 0.0001). The proportion with severe valvulopathy increased from 20% (6a30) to 66% (29a44), as fen¯uramine dosage increased from 40 mgad to !60 mgad. Compared with patients taking`40 mgad fen¯uramine, patients taking !60 mgad had an adjusted or of 9.2 (95% con®dence interval 2.1 ± 40.8) for severe valvulopathy ( Table 2 ). The Hosmer and Lemeshow goodnessof-®t tests indicated that the logistic model ®ts the data well with goodness-of-®t statistic 1.3 (P 0.9961). 8 In contrast, both phentermine dosage and duration of drug use did not appear to be related to the severity of valvulopathy.
Discussion
This is the ®rst study to suggest that the severity of cardiac valvulopathy was associated with fen¯ura-mine dosage, but not with phentermine dosage. Among patients with valvulopathy, those with severe valvulopathy were substantially more likely to have taken a higher dose of fen¯uramine (!60 mgad) than those with less severe valvulopathy.
The mechanism of the drug-associated valvulopathy is unclear. It has been speculated that serotonin might be the link, because the injured valves look identical to those observed in carcinoid-induced valvular disease. 1 An additional hypothesis is that phentermine may impair the clearance of serotonin by the lung, which would allow abnormally high concentrations of serotonin to reach the left side of the heart, when it is taken together with fen¯uramine. 9, 10 Because all the subjects in this study were treated with both fen¯uramine and phentermine, we cannot reject the possibility that the dose-effect of fen¯ur-amine on the severity of valvulopathy may have a phentermine-related threshold.
Because data on initial body weight were not provided, weight at the time of report was used as a proxy. Patients with severe valvulopathy had a signi®cantly higher weight at the time of report than those with less-severe valvulopathy, which may re¯ect differences in initial weight. Nevertheless, the effect of fen¯uramine dosage on severity of valvulopathy cannot be ascribed to differential body weight, because weight was not signi®cantly related to severity of valvulopathy in the logistic models.
Although a previous study showed an association of valvulopathy with the duration of drug use, 5 duration of drug use did not appear to be related to the severity of valvulopathy in this MEDWATCH data. There are several explanations. First, the duration of exposure depended upon the reporting physician's recall and may have been underestimated for those patients who had previously used appetite-suppressants under the care of other physicians. Second, cardiac disorders may occur as early as a few weeks after drug exposure, 6 whereas 93% of all patients in this study had taken the drug for at least 3 months, with a median duration of 11 months. Therefore, this data set lacks Percentage may not add up to 100 because of rounding-off. *P`0.05. Severity of valvulopathy and fen¯oramine use R Li et al suf®cient data on short duration use to determine the independent effect of duration.
Because not all fen-phen users with valvulopathy see physicians, and not all cases of valvulopathy seen by physicians were reported to MEDWATCH, selection bias could have occurred in this study. However, because the most frequently used dosage for fen¯ur-amine was 60 mgad, which was the standard dosage, selection of severe valvulopathy cases for reporting was unlikely to be related to the dosage. In this case, our results would be unbiased. 11 Because echocardiography was not standardized across cardiologists, diagnostic misclassi®cation may also have occurred. If this misclassi®cation was unrelated to the dosage (non-differential misclassi®cation), then our results would be biased towards the null.
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This study also suggests common off-label drug use in the USA. For fen¯uramine, the recommended dosage was 60 mgad for a few weeks with a total dosage not to exceed 120 mgad. 12 However, 9% of all patients in this study took more than 60 mgad fenuramine (maximum dosage 220 mgad) and 72% of all patients took fen-phen for more than 6 months (maximum duration 39 months). Although the combination use of fen-phen was not approved by FDA, it was also widely used and the majority of case reports received by FDA through MEDWATCH system were fen-phen users.
Conclusion
Based on our results we conclude that, among patients with drug-associated valvulopathy, the risk of clinically severe valvular heart disease increased markedly at a fen¯uramine dose !60 mgad. This ®nding is important in understanding the nature of the drugassociated valvulopathy and providing appropriate care to patients exposed to fen¯uramine.
